The Future of Hospital Acquired Infection Control Market
The hospital acquired infection control market is projected to reach $31.3 billion by 2026, Provides crucial industry insights that will help your business grow.
[304 Pages Report] The hospital acquired infection control market is projected to reach USD 31.3 billion by 2026 from USD 29.1 billion in 2021, at a CAGR of 1.5% during the forecast period. The growth of the hospital acquired infection control market can largely be attributed to factors such as the high incidence of hospital-acquired infections, the increasing number of surgical procedures, the growing geriatric population and the increasing incidence of chronic diseases, technological advancements in terilization equipment, and the growing awareness of environmental & personal hygiene due to COVID-19.
The increasing use of E-beam sterilization, reintroduction of ethylene oxide sterilization, and the growing healthcare industry and outsourcing of operation to emerging countries are expected to offer high-growth opportunities for market players during the forecast period.
Temporary hospitals are also being set up to deal with the growing number of cases. Hence, the spread of COVID-19 has spurred a surge in demand for HAI services due to the growing cases of HAIs in hospital settings.
Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=204343466
Various measures are being taken by companies as well as government bodies to drive market growth. For instance, the FDA has recommended that Sterigenics should reopen its ethylene oxide-based sterilization plant in the US.
The plant had been shut due to harmful emissions, which were believed to be carcinogenic. In March 2020, the company received permission to reopen the plant for 21 days to sterilize PPE for healthcare workers to use during the COVID-19 pandemic. Such developments are anticipated to drive the growth of this market.
The increasing number of temporary hospitals, the growing need for remote care, and the rising influx of COVID-19 patients have resulted in the expansion of healthcare infrastructure and driven the demand for efficient hospital acquired infection control products and services.